Sebaceous Neoplasms
Sebaceous neoplasms are a spectrum of skin growths, from benign to malignant, that arise from abnormal proliferation of oil-producing cells (sebocytes). Identifying them correctly matters not only for treating the lesion itself but also because they can be the first clue to an underlying inherited condition such as Muir-Torre syndrome.
Structural Features of Sebaceous Neoplasms
Sebaceous neoplasms fall into four main types, based on how differentiated the cells are and the proportion of mature sebocytes to basaloid cells:
| Lesion | Biological nature | Clinical significance |
|---|---|---|
| Sebaceous hyperplasia | Benign enlargement | Common in older adults; pale yellow papules with a central dip on the face. |
| Sebaceous adenoma | Benign neoplasm | The most important marker of Muir-Torre syndrome. |
| Sebaceoma (sebaceous epithelioma) | Benign / borderline neoplasm | Easily mistaken for basal cell carcinoma; also linked to Muir-Torre syndrome. |
| Sebaceous carcinoma (SC) | Malignant tumor | Highly malignant; prone to recurrence and to spread to lymph nodes and internal organs. |
Treatment Strategy and Clinical Management at Haute-Derma
Surgery
- Mohs micrographic surgery (MMS): The treatment of choice (gold standard) for sebaceous carcinoma, particularly around the eye. Mohs surgery checks 100% of the margins on fresh tissue, cuts the local recurrence rate to under 5% and preserves as much of the eyelid's vital anatomy as possible.
- Wide local excision (WLE): Used when Mohs surgery is not available, with a minimum safety margin of 5–6 mm and intraoperative frozen-section margin control.
Sentinel Node Assessment and Systemic Treatment
- Sentinel lymph node biopsy (SLNB): Considered for periocular sebaceous carcinoma larger than 10 mm, tumors with a high mitotic rate or vascular/perineural invasion, and recurrent disease.
- Radiotherapy: Given as adjuvant treatment after surgery when tumor cells remain at the margins and further surgery is not possible, or as palliative treatment for patients who cannot undergo surgery.
- Immunotherapy: Immune checkpoint inhibitors (such as the anti-PD-1 antibody pembrolizumab) have shown strong results in locally advanced or metastatic sebaceous carcinoma with mismatch repair deficiency (dMSI/dMMR).